title: [Cystoid macular oedema after fingolimod treatment in multiple sclerosis].
abstract: METHODS
  A woman, treated with immunomodulatory and immunosuppressive drugs for multiple sclerosis, developed macular oedema 4 months after oral fingolimod administration. The patient was previously seen by an ophthalmologist, with a normal anterior segment and funduscopic examination. Four months after the treatment she referred to decreased visual acuity in both eyes. The funduscopic and OCT examination now revealed cystoid macular oedema (CME).
  
  
  CONCLUSIONS
  Attention to visual changes and periodic funduscopic examinations are an important part of monitoring while using fingolimod. In our patient early recognition and discontinuation of fingolimod did not result in resolution of the CME.
authors.affiliation: Servicio de Oftalmología, Hospital Clínico Universitario, Valladolid, España. Electronic address: victor_asensio@orangemail.es.
authors.forename: V M
authors.initials: VM
authors.lastname: Asensio-Sánchez
authors.affiliation: Servicio de Oftalmología, Hospital Clínico Universitario, Valladolid, España.
authors.forename: L
authors.initials: L
authors.lastname: Trujillo-Guzmán
authors.affiliation: Servicio de Oftalmología, Hospital Clínico Universitario, Valladolid, España.
authors.forename: R
authors.initials: R
authors.lastname: Ramoa-Osorio
mesh_terms: D000328:Adult; D005260:Female; D000068876:Fingolimod Hydrochloride; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D008269:Macular Edema / Q000139:chemically induced*; D009103:Multiple Sclerosis / Q000188:drug therapy*; D011409:Propylene Glycols / Q000009:adverse effects*; D013110:Sphingosine / Q000009:adverse effects / Q000031:analogs & derivatives*
chemical_list: D007166:Immunosuppressive Agents; D011409:Propylene Glycols; D000068876:Fingolimod Hydrochloride; D013110:Sphingosine
keywords: Agudeza visual; Edema macular; Esclerosis múltiple; Fingolimod; Irreversible; Macular oedema; Multiple sclerosis; Visual acuity